VARITHENA
Peakpolidocanol
NDAINTRAVENOUSSOLUTION
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
4/8 — Partial
VARITHENA (polidocanol) is sclerosing activity [moa]. First approved in 2013.
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VARITHENA (polidocanol) is an intravenous sclerosing agent approved in 2013 for the treatment of varicose veins through foam sclerotherapy. It works by causing inflammation and fibrosis of the vein wall, leading to vein closure and resorption. The product delivers polidocanol in a microfoam formulation that improves contact with vessel endothelium.
Peak5.6 years to LOE
Product is at peak lifecycle stage with established market presence; commercial teams are focused on market penetration and optimization rather than launch activities.
Mechanism of Action
Sclerosing Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)
Started Feb 2023
43 enrolled
Varicose Veins
Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
Started Sep 2017
76 enrolled
Venous Leg Ulcer
Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)
Started Aug 2011
21 enrolled
Varicose Veins
Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Started Dec 2010
279 enrolled
Varicose Veins
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Started Nov 2010
235 enrolled
Varicose Veins
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.